JPMorgan Starts Syndax Pharmaceuticals (SNDX) at Overweight

January 3, 2023 12:37 AM EST Send to a Friend
JPMorgan analyst Anupam Rama initiates coverage on Syndax Pharmaceuticals (NASDAQ: SNDX) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login